The Image of a Hero in Western and Russian Social Advertising

Autor: A. G. Zhukova, E. A. Kartushina, A. S. Mamontov

Publikováno v: Научный диалог, Vol 0, Iss 12, Pp 21-42 (2019)

The article is devoted to a comparative study of the image of a hero / superhero in Russian and Western social advertising. The relevance of the study is determined by the contrast of globalization processes, on the one hand, and the desire to preser

Externí odkaz: https://doaj.org/article/e3053143787c4b9d9daa9bb8ab3a8385

Tissue Specificity of a Response of the Pro- and Antioxidative System After Resuscitation

Autor: A. G. Zhukova, T. G. Sazontova, Yu. V Zarzhetsky, A. V. Volkov, V. V. Moroz

Publikováno v: Общая реаниматология, Vol 1, Iss 3, Pp 46-53 (2005)

This investigation was undertaken to study the resistance of membrane structures and the level of the intracellular defense systems of the heart, brain, and liver in animals with active versus passive behavior in different periods (days 7 and 30) aft

Externí odkaz: https://doaj.org/article/0e02b274f8474e359dd1de5a41600b2d

Particularities of arterial stiffness dynamics on the background of breast cancer chemotherapy

Autor: Elena N. Yushchuk, Elizaveta G. Medvedeva, Daria A. Filonenko, Svetlana V. Ivanova, Liudmila G. Zhukova, Daria A. Sapunova

Publikováno v: Терапевтический архив, Vol 95, Iss 8, Pp 621-626 (2023)

Background. Modern breast cancer chemotherapy regimens (BC) consider individual patient parameters and ranges of cardiotoxic doses. However, clinicians often record clinical and laboratory-instrumental signs of cardio- and vasculotoxicity in patients

Externí odkaz: https://doaj.org/article/a52888df66f145b2bdfe73a8d65a0a3d

The effect of CDK4/6 inhibitors on the overall survival in patients with advanced HR+/HER2- BC in the entire population and in special clinical subgroups of unfavorable prognosis: A review

Autor: Katerina S. Grechukhina, Maxim V. Kalugin, Andrey A. Prosvirnov, Margarita V. Sukhova, Liudmila G. Zhukova

Publikováno v: Современная онкология, Vol 25, Iss 1, Pp 55-62 (2023)

An increase in the median progression-free survival when using cyclin-dependent kinase 4/6 inhibitors in combination with aromatase inhibitors led to high expectations from the analysis of the overall survival of patients with HR+/HER2- metastatic br

Externí odkaz: https://doaj.org/article/c5a35aa69a34445b8837d2b8b2b42e5a

Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study

Autor: Kristina V. Orlova, Mikhail Yu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov, Petr R. Goldshmidt, Aleksandra F. Saydullaeva, Dary V. Bogacheva, Marina A. Yavorskaya, Artur Z. Azanov, Alexander A. Fedenko, Larisa V. Bolotina, Tatyana I. Deshkina, Kseniya G. Babina, Ekaterina A. Kuzevanova, Liudmila G. Zhukova, Polina S. Feoktistova, Natalya I. Polshina, Ekaterina V. Peganova, Valentina E. Shikina, Maksim M. Sobolev, Oleg V. Mironov, Vera A. Vaschenko, Mariya M. Ershova, Agniya O. Mezhueva, Svetlana A. Orlova, Denis A. Tantsyrev, Darya K. Taskina, Antonina A. Teterich, Elena V. Karabina, Yuliya V. Kostalanova, Marina V. Bogacheva, Natalia V. Zhukova, Rashida V. Orlova, Maksim V. Zinkevich, Aleksandr I. Kazmin, Mikhail V. Volkonskiy, Liya M. Voronkova, Anastasiya S. Karpova, Mikhail L. Maleyko, Mariya N. Gorshenina, Elena I. Kryuchkova, Fedor V. Moiseenko, Yuliya I. Murzina, Shamil I. Musin, Andrey N. Ogloblin, Mariya S. Perminova, Regina A. Dumbrava, Sergey A. Emelyanov, Svetlana A. Protsenko, Alexander V. Sultanbaev, Anna V. Tarasova, Elena B. Shakhnovich, Marina V. Demchenkova, Yuliya A. Lozovskaya, Khedi S. Musaeva, Elena M. Pavlova, Roman A. Skotnikov, Vera V. Chernova, Angelina S. Chichkanova, Adina M. Akhmatova, Marina A. Zafirova, Andrey A. Mischenko, Elena N. Ovsienko, Viktoriya A. Petrukhnenko, Oksana A. Syusyukaylova, Yana A. Tyugina, Elena A. Shumilkina, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Pavel L. Baldin, Anastasiya S. Belova, Olga V. Diduk, Elena A. Konovalova, Lyudmila N. Lebedeva, Yaroslav A. Li, Viktoriya V. Mashtapa, Yana A. Mironenkova, Kristina V. Narovenkova, Olga A. Pavlikova, Elvira L. Parsadanova, Irina S. Pimonova, Anna A. Ruzhnikova, Irina D. Sivunova, Ekaterina P. Soloveva, Maksim I. Sosnin, Toita Kh. Temirsultanova, Makhabbat Zh. Tyulegenova, Aleksandra V. Khodkevich, Nadezhda R. Shakurova, Sureya N. Efendieva, Karine L. Avagimyan, Ekaterina P. Anokhina, Mariya I. Antoshkina, Stanislav M. Borzyanitsa, Samir K. Dzhentemirov, Marina V. Dmitrochenko, Alla V. Zheleznyak, Yuliya V. Komoza, Aleksandr S. Kopanev, Tatyana I. Kornienko, Margarita A. Krasilnikova, Darya A. Lukhmanova, Natalya S. Mazur, Polina M. Markina, Zhargal S. Mitapov, Svetlana N. Osodoeva, Irina A. Prokopenko, Irina M. Radyukova, Madina S. Ramazanova, Alfiya R. Safarova, Mariya A. Safronova, Khalimat M. Khabrieva, Natalya S. Tsygankova, Kseniya V. Chermakova, Tatyana A. Chirkova, Igor V. Samoylenko, Valeria V. Nazarova, Angelina E. Akhmetyanova, Lev V. Demidov

Publikováno v: Современная онкология, Vol 24, Iss 4, Pp 413-425 (2023)

Background. Novel agents immune checkpoint inhibitors fundamentally changed the prognosis for life in patients with metastatic and/or inoperable melanoma. The development, studies, and approval of a new original PD1 inhibitor in Russia in 2020 prompt

Externí odkaz: https://doaj.org/article/0a4a24e511dc43ae8f376adaefc2b0a8